France· FR:64423080
DUPIXENT 200 mg, solution injectable en seringue préremplie
A dupilumab product containing dupilumab, registered in France by SANOFI WINTHROP INDUSTRIE, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Dupilumab is registered in 16 of 19 countries.
Countries holding a registration under ATC D11AH05 (dupilumab), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Dupilumab · ATC D11AH05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dupilumab costs, country by country.
Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dupilumab · price per daily dose (21.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$72.07
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DUPILUMAB
- Manufacturer
- SANOFI WINTHROP INDUSTRIE
- Country
- France (FR)
- ATC code
- D11AH05
- ATC class
- Dupilumab
- Defined daily dose
- 21.4 mg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip1334009301776931 seringue(s) préremplie(s) en verre siliconé(e) de 1,14 ml avec dispositif(s) de sécurité de l'aiguilleEUR 596.34
- cip1334009301777092 seringue(s) préremplie(s) en verre siliconé(e) de 1,14 ml avec dispositif(s) de sécurité de l'aiguilleEUR 1.16
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
56 interactions on record for dupilumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dupilumab · interactions on record
56 records
- 27 severe
- 22 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dupilumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandDupixent 200 mg solution for injection in pre-filled penSanofi Winthrop Industrie
- NetherlandsDupixent 200 mg oplossing voor injectieSanofi Winthrop Industrie
- CzechiaDUPIXENTSanofi Winthrop Industrie, Gentilly
- United StatesDupixentSanofi-Aventis U.S. LLC
- ItalyDUPIXENT*1 penna preriempita SC 200 mg 1,14 mlSANOFI WINTHROP INDUSTRIE
- FinlandDupixentSanofi Winthrop Industrie
- SwitzerlandDupixent
- BelgiumDupixent 100 mgSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Dupixent
- Iceland · Dupixent
- Liechtenstein · Dupixent
- Norway · Dupixent
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3b0cf19b-e62d-454f-92f3-befa0898e71d GET /v1/drugs/3b0cf19b-e62d-454f-92f3-befa0898e71d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64423080",
"date_amm": "2019-05-06",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1229",
"substance": "DUPILUMAB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about dupilumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.